Biopharmaceutical Manufacturing, Upstream, Downstream processing news

Headlines

Novavax's vaccine candidate is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and Matrix‑M adjuvant. Pic:getty/ca-ssis

Novavax starts UK Phase 3 trial of COVID-19 vaccine

Novavax has initiated its first Phase 3 trial to evaluate the efficacy, safety and immunogenicity of its COVID-19 vaccine candidate.

BMS, bluebird bio CAR-T therapy may see US approval by early 2021

Bristol Myers Squibb (BMS) and bluebird bio say the FDA has accepted their application on their multiple myeloma CAR-T cell therapy, ide-cel.

Content provided by Yourway

Staying Ahead of COVID-19

The pandemic remains a globally disruptive entity that can impede efficacy of clinical trials. Choosing the right partner helps you concentrate on obtaining optimal results from at-home populations.

Johnson & Johnson starts Phase 3 trial for COVID-19 vaccine

Johnson & Johnson has launched its pivotal global Phase 3 trial for its COVID-19 vaccine candidate: anticipating the first batches of its vaccine will be available for emergency use authorization in early 2021.

AZ vaccine study still on hold in the US, lawmakers hear majority of Americans remain susceptible to COVID-19

AstraZeneca's phase 3 COVID-19 vaccine trial remains on hold in the US as the FDA probe into a patient illness in the UK trial that initiated the global pause continues, the US Department of Health and Human Services Secretary, Alex Azar, told US...

Using HSV helper viruses to increase AAV production

Recognizing the industry-wide need to improve adeno-associated virus (AAV) vector manufacturing, Applied Genetic Technologies Corporation (AGTC) has adopted changes intended to increase yield and purity.